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Summary
Background The relative importance of previous diagnosis and hereditary prothrombotic risk factors for cerebral 
venous thrombosis (CVT) in children in determining risk of a second cerebral or systemic venous thrombosis (VT), 
compared with other clinical, neuroimaging, and treatment variables, is unknown.
Methods We followed up the survivors of 396 consecutively enrolled patients with CVT, aged newborn to 18 years 
(median 5·2 years) for a median of 36 months (maximum 85 months). In accordance with international treatment 
guidelines, 250 children (65%) received acute anticoagulation with unfractionated heparin or low-molecular weight 
heparin, followed by secondary anticoagulation prophylaxis with low-molecular weight heparin or warfarin in 
165 (43%). 
Results Of 396 children enrolled, 12 died immediately and 22 (6%) had recurrent VT (13 cerebral; 3%) at a median of 
6 months (range 0·1–85). Repeat venous imaging was available in 266 children. Recurrent VT only occurred in 
children whose ﬁ rst CVT was diagnosed after age 2 years; the underlying medical condition had no eﬀ ect. In Cox 
regression analyses, non-administration of anticoagulant before relapse (hazard ratio [HR] 11·2 95% CI 3·4–37·0; 
p<0·0001), persistent occlusion on repeat venous imaging (4·1, 1·1–14·8; p=0·032), and heterozygosity for the 
G20210A mutation in factor II (4·3, 1·1–16·2; p=0·034) were independently associated with recurrent VT. Among 
patients who had recurrent VT, 70% (15) occurred within the 6 months after onset. 
Conclusion Age at CVT onset, non-administration of anticoagulation, persistent venous occlusion, and presence of 
G20210A mutation in factor II predict recurrent VT in children. Secondary prophylactic anticoagulation should be 
given on a patient-to-patient basis in children with newly identiﬁ ed CVT and at high risk of recurrent VT. Factors that 
aﬀ ect recanalisation need further research.
Introduction
Although cerebral venous thrombosis (CVT) is associated 
with substantial mortality and morbidity,1,2 its causes in 
children have not been intensively investigated, mainly 
because it occurs at a low frequency, estimated at 0·67 per 
100 000 children.1 A wide range of underlying conditions1–12 
and symptoms at clinical presentation1–3 has been 
reported. Additionally, some subclinical factors, including 
prothrombotic disorders, are thought to contribute to 
presentation with the condition.2,7,13–28 
The long-term risk of a second cerebral or systemic 
venous thrombosis (VT) has received little attention, 
although overall proportions of such events were 
remarkably similar in two series with follow-up of 
18 months and 12 months (13% and 12%).1,2 The relevance 
of predisposing factors to the risk of recurrence, 
compared with other clinical and neuroimaging 
information, is not known. Partial or complete 
recanalisation has been documented in the majority of 
patients undergoing repeat venous imaging,2,26 although 
16% had persistent occlusion in both large series,2,26 but 
the possibility that this problem is a risk factor for 
recurrent VT has not been assesed in children. 
Additionally, owing to the absence of appropriate 
randomised clinical treatment studies, guidelines for 
anticoagulation in children with VT are mainly adapted 
from adult protocols.13,29,30 We therefore investigated, in a 
European cohort study, the relevance of age at onset, 
underlying medical conditions, mode of administration 
of anticoagulation, neuroimaging data, and prothrombotic 
risk factors to a second VT in paediatric patients with a 
ﬁ rst CVT onset. The primary study objective was to 
calculate the symptomatic recurrence rate per 
1000 person-years. Secondary aims were to calculate the 
time to recurrence, to examine the relevance of clinical, 
laboratory, and radiological risk factors to symptomatic 
recurrence, and to identify number needed to treat or to 
screen to prevent recurrence. 
Methods
Study design and population
The multicentre follow-up study was done in accord with 
the ethics standards laid down in the updated version of 
the 1964 Declaration of Helsinki and was approved by the 
medical ethics committee of the University of Münster, 
Germany. Consecutively admitted term neonates and 
children with newly diagnosed CVT were enrolled in the 
German prospective cohort, with written parental 
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consent. Appropriate research ethics approval was 
obtained from the institutional ethics review board at 
each site to include data of consecutively enrolled patients 
in England (anonymised clinical data from prospective 
stroke registries), Belgium, and Israel.
The present study was a multicentre cohort study to 
assess the rate of symptomatic VT recurrence per 1000 
person-years after a ﬁ rst onset of CVT. The core protocol 
was developed by the German collaborative group and 
was adopted contemporaneously by centres in Belgium, 
England, and Israel; data were pooled across these sites 
to ascertain whether the results were generalisable, and 
to increase power for the secondary aims, which were to 
assess time to recurrence, predictors of recurrence, and 
number needed to screen for this relatively rare event. 
From July, 1996, to August, 2005, 396 patients from 
Belgium (n=5), Germany (n=299), Israel (n=53), and 
the UK (n=39) were analysed in the European paediatric 
database located in Münster, Germany. Consecutive 
patients with a ﬁ rst symptomatic CVT were recruited 
whether or not prothrombotic risk factors were present 
and recurrence was ascertained at follow-up in survivors. 
Preterm infants and patients older than 19 years at 
onset were excluded. First CVT was diagnosed locally 
by standard imaging methods—ie, Duplex sonography 
(neonates only), magnetic resonance imaging (MRI), 
and computed tomography (CT) or magnetic resonance 
venography and angiography.1,25,26,31,32
Procedures
As previously described, bacterial or viral infections, head 
or vascular trauma, surgery, dehydration, immobilisation 
(bed rest >4 days) or obesity (body-mass index [BMI] 
>90th age-dependent percentiles33), jugular or subclavian 
central venous lines, solid tumours, leukaemia and 
lymphomas, anaemia, autoimmune diseases, renal 
diseases, metabolic disorders, birth asphyxia, and cardiac 
malformations were predeﬁ ned as predisposing clinical 
conditions.25–29 Additionally, use of drugs such as steroids 
and Escherichia coli asparaginase, sympathomimetics, 
coagulation factor concentrates, or oral contraceptives, 
and nicotine abuse were classiﬁ ed as likely triggers. 
Patients who had CVT but did not show one of the criteria 
for a predisposing condition or trigger were classiﬁ ed as 
previously healthy.25 
Patency of the cerebral veins in patients originally 
diagnosed with MRI and MR venography (MRV) was 
documented by use of MRI and MRV, 3–6 months after 
acute CVT onset, and was mainly classiﬁ ed centrally by 
one experienced paediatric neuroradiologist in Israel, 
Germany, or Belgium and the UK, on these radiological 
criteria:1,25,26,31,32 complete patency if no clot was present in 
the previously aﬀ ected vessel; partial patency if the clot 
inside the lumen seemed to have decreased or shrunk; 
no change if the thrombus remained of similar size and 
extent in the same lumen; or extension if the clot 
extended to previously unaﬀ ected vessels. Recurrent 
CVT was diagnosed when MRI and MRV done in the 
acute phase of a new vascular accident showed fresh 
thrombotic material within a lumen of the vein—ie, a 
new intraluminal ﬁ lling defect, compared with the 
results of previous tests. Incidental cases of apparent 
recurrence that were diagnosed without interim imaging 
while the patient was asymptomatic, and children in 
whom the ﬁ rst CVT was not conﬁ rmed by MRV, were 
excluded from analyses that assessed predictors of 
recurrent CVT.
VT in the deep veins of the leg and pulmonary embolism 
were diagnosed when standard imaging methods (ie, 
compression sonography, venography, CT, spiral CT, or 
MRI and perfusion lung scans for pulmonary embolism) 
in the acute phase of a new vascular accident showed 
fresh thrombotic material within a lumen of the vein. 
According to published paediatric treatment guidelines 
for anticoagulation,13,29,30 patients were treated on an 
individual basis with low molecular weight heparin 
(LMWH), or unfractionated heparin followed by warfarin 
without knowledge of whether the patient was a carrier of 
prothrombotic risk factors or not. Long-term 
anticoagulation was deﬁ ned as secondary prophylactic 
treatment with administration of anticoagulation for 
longer than 4 weeks. 
Routine diagnostic tests done by the participating centres 
included face-to-face physical and neurological examination 
by an experienced paediatrician and assessment by 
standard imaging methods, at ﬁ rst thrombotic onset and 
at 8–12 weeks and 6 months later (before withdrawal of 
anticoagulation). Because of the limited availability and 
variability across participating centres, MRV was done to 
assess follow-up patency rates within 3–6 months. In 
children with clinically suspected CVT recurrence, MRI 
and MRV were done within a 48-h window (allowing for 
unavailability at weekends) after emergency CT, 
immediately after hospital admission. Local reports were 
accepted for emergency imaging at initial presentation, 
but for the majority of follow-up MRI and MRV procedures, 
independent reading was available from the study centres 
(London, Tel Hashomer, and Münster). Since very few 
cases occurred in Belgium, data for this country were 
analysed together with those from the UK.2 After 
discontinuation of anticoagulation, asymptomatic patients 
were followed-up every few months for the ﬁ rst year and at 
longer intervals thereafter (at least yearly). All patients were 
seen at least once for a follow-up with a paediatric 
neurologist.
Laboratory analyses for thrombophilic factors associated 
with risk of VT in children, including those for the presence 
of the G1691A mutation in factor V, the G20210A mutation 
in factor II, antithrombin, protein C, protein S, and 
antiphospholipid antibodies or lupus anticoagulants were 
done in the participating study centres for 367 patients, as 
previously described.2,22,23,26,27 Analysis of lipoprotein (a), 
reported to be a risk factor for arterial stroke in children 
in 1997,14,23 was undertaken in 200 patients. 
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Statistical analyses
For the primary study objective, to calculate the 
symptomatic recurrence rate per 1000 person-years, 
based on the recruitment period of 9 years and a 
median follow-up period of 36 months, the sample size 
was n=384 (survivors) with 22 symptomatic recurrences 
diagnosed. Predictors that could possibly aﬀ ect the study 
outcomes, deﬁ ned a priori on the basis of published data, 
were: age at onset, administration of anticoagulants 
before relapse (relapse on anticoagulation treatment), 
patency rates, and prothrombotic risk factors signiﬁ cantly 
associated with a ﬁ rst VT onset.1,13,18,21–35 Using a rule of 
thumb for proportional hazards analysis including about 
ten outcomes for each independent predictor,36 the ﬁ nal 
statistical model included three predictors, which were 
obtained from results of univariate survival analysis (ﬁ rst 
step). A second step calculated the possible eﬀ ect of three 
prothrombotic risk factors—factor V G1691A mutation, 
factor II G20210A mutation, and raised lipoprotein 
(a)—on recurrent VT. Signiﬁ cant predictors from both 
steps were included in the ﬁ nal multivariate analysis. 
Model assumptions and goodness-of-ﬁ t were assessed 
using the Hosmer and Lemeshow goodness-of-ﬁ t test 
(SAS version 8.3).37 As binary outcomes of interest, 
anticoagulation treatment before relapse (yes, no), 
persistent venous occlusion (yes, no), and presence of 
factor II G20210A mutation (thrombophilic gene 
mutation known to increase risk of VT in children;22 yes, 
no) were incorporated in the model. Further statistical 
analyses were done with Stata (version 8.0) and StatView 5 
software (SAS Institute). The recurrence rates were 
calculated as the number of recurrent VTs per 
1000 person-years. The secondary study objective, time to 
recurrence, calculated as the probability of thrombosis-free 
survival as a function of time, was assessed by 
Kaplan-Meier univariate analysis. The log-rank test was 
used to test for diﬀ erences in thrombosis-free survival 
between groups. Patients were censored from the survival 
analysis at either death unrelated to VT recurrence or 
loss to follow-up, using data from the last clinical 
follow-up visit. To evaluate an independent contribution 
to the risk of recurrent VT and to adjust for potential 
confounders, the hazard ratio (HR) and 95% CI were 
estimated from Cox’s proportional hazards model. 
Possible interaction eﬀ ects between predictors were 
assessed with the Wald test (SAS version 8.3). To further 
test the overall hypothesis of no eﬀ ect of all predictors 
the likelihood ratio test was done. Continuous data are 
presented as median (range) and were assessed by 
non-parametric statistics with the Wilcoxon-Mann-Whitney 
U test or Kruskal-Wallis test. To compare frequency 
distributions of fatal outcome, the χ² test or Fisher’s exact 
test was used. In a subset of German patients the degree 
of agreement beyond chance between local and central 
readers were measured with the κ statistics (Stata 8.0). 
The criterion for statistical signiﬁ cance was set at α=0·05. 
p values were based on two-sided tests. Numbers needed 
to treat and numbers needed to screen were calculated as 
previously described.38
Role of the funding source
The funding sources of the study had no role in study 
design, data collection, data analysis, data interpretation, 
or in writing of the report. The corresponding author had 
access to all data and had ﬁ nal responsibility for 
submitting the report for publication.
Results
Table 1 summarises patients’ characteristics at ﬁ rst 
thrombotic onset. MRI was undertaken at initial 
presentation in 379 (95%) cases. 12 children died within 
2 weeks of presentation with a ﬁ rst episode of CVT, one 
of whom had received anticoagulation. Causes of deaths 
Israel (n=53) Germany 
(n=299)
UK/Belgium 
(n=39/5)
Total (n=396)
Population at ﬁ rst CVT onset 
White 46 (87%) 299 (100%) 37/5 (95%/100%) 387  (98%)
Arab 7 (13%) 0 0 7 (2%)
Afro-Caribbean 0 0 2/0 (5%/0%) 2 (1%)
Male 28 (56) 180 (60) 28 (64%) 236 (60%)
Median age, years (range) 3 (0·01–17·7) 6 (0·01–17·9) 6 (0·1–14) 5 (0·01–17·9)
Number of neonates 9 (17%) 66 (22%) 0 75 (19%)
Venous sinuses involved at onset, infarction, haemorrhage
Superﬁ cial
Sagittal 25 (47%) 153 (51%) 10 (23%) 188 (47.5%)
Transverse 10 (19%) 34 (11%) 2 (4.5%) 46 (12%)
Sigmoid 5 (10%) 21 (7%) 1 (2.3%) 27 (7%)
Deep venous system
Deep veins 1 (2%) 3 (1%) 0 4 (1%)
Straight sinus 1 (2%) 2 (0.7%) 1 (2.3%) 4 (1%)
Cavernous 0 2 (0.7%) 5 (11%) 7 (2%)
Other locations
Cortical veins 0 1 (0.3%) 2 (4.5%) 3 (1%)
Multiple (>2 sinuses 
involved)
11 (22%) 83 (28%) 23 (52%) 117 ( 30%)
Infarction on initial imaging 8 (15%) 25 (8%) 12 (27%) 37 (9%)
Haemorrhage on initial 
imaging
3 (6%) 18 (6%) 12 (27%) 33 (8%)
Anticoagulation, underlying conditions, acute deaths
Anticoagulation withheld 
because of haemorrhage on 
initial imaging
2 (4%) 15 (5%) 6 (13%) 23 (6%)
Underlying medical 
conditions present
34 (68%) 183 (61%) 23 (53%) 240 (61%)
Deaths after CVT onset 3 (6%) 5 (2%) 4 (9%) 12 (3%)
Acute anticoagulation given 48 of 53 (91%) 185 of 299 (62%) 17 of 44 (39%) 250 of 396 (63%)
LMWH 32 (68%) 92 (50%) 3 (18%) 128 (51%)
Unfractionated heparin 15 (32%) 93 (50%) 14 (82%) 122 (49%) 
In patients who died 
immediately
1 0 0 1 of 12 (8%)
Data are number (%) unless otherwise stated. Cohort data previously published in part.2,26,27
Table 1: Clinical characteristics of CVT study population at thrombotic onset
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were severe infection in three, intracranial bleeding in 
two, and brain herniation after severe brain oedema in 
seven cases. The risk of a second VT was assessed in 
384 consecutively recruited children aged neonatal to 
18 years (median 5·2 years; 236 boys [60%]) who survived 
a ﬁ rst episode of CVT, and who were followed up for a 
median time of 36 (range 0·1–85) months. Detailed data 
of the follow-up group are summarised in table 2. When 
comparing children aged 2 years or younger with those 
older than 2 years, we noted no signiﬁ cant diﬀ erences 
with respect to sinuses involved at ﬁ rst thrombotic 
onset (p=0·164) and methods of treatment used (p=0·657). 
Additionally, we found no signiﬁ cant diﬀ erence between 
the groups with respect to imaging methods used 
(p=0·511).
A second VT event occurred in 22 of 384 surviving 
children at a median of 6 months (range 0·1–85) after 
the ﬁ rst event, and at a median age of 13 years 
(range 2·5–16·2), with no signiﬁ cant diﬀ erence between 
countries in the proportion with a second event (table 2; 
p=0·309).The recurrence rate per 1000 person-years was 
21·2 (95% CI 13·9–32·1) for the entire cohort and 
29·1 (18·9–44·7) for children older than 2 years. At 
recurrence, immediate death occurred in two of 22 cases 
due to haemorrhage with severe brain oedema and 
herniation. The distribution of recurrent VT and the 
VT-related death rates recorded are shown in table 3. Five 
children died due to their basic disease after the end of 
the median follow-up period (36, 38, 47, 48, and 50 months 
after ﬁ rst CVT onset). About 70% of recurrent VT events 
occurred within the ﬁ rst 6 months after the initial CVT. 
Recurrent VT occurred within the veins of the brain in 13 
of 22 cases (59%); deep venous thrombosis of the legs and 
pelvis was diagnosed in eight cases (in two cases associated 
with CVT recurrence, table 2), pulmonary embolism in 
two, and intracardiac thrombosis in one. A bivariate 
analysis showed no signiﬁ cant diﬀ erence between 
recurrence of CVT and VT in other locations with respect 
to the predictor variables chosen (persistent venous 
occlusion [CVT] p=0·966; anticoagulation before relapse 
p=0·146; factor II G20210A mutation p=0·999). Brain 
lesions at second VT were documented as new thrombus 
formation in previously unaﬀ ected segments, a new 
vascular ﬁ lling defect of the internal cerebral veins, 
cortical veins, or within the contralateral transverse sinus. 
No child aged 2 years or younger with initial CVT showed 
recurrent VT during the follow-up period. The youngest 
child with recurrent VT had the ﬁ rst CVT event aged 
25 months. Compared with the average age of the entire 
study cohort (5·2 years) the median age of patients who 
had a recurrence was 13 years. Cumulative thrombosis-free 
survival with respect to age at ﬁ rst thrombosis onset is 
presented in ﬁ gure 1; the log-rank test showed a signiﬁ cant 
diﬀ erence between the two curves. 
 Before recurrent VT, 17 of 22 children aﬀ ected (77·3%) 
were suﬀ ering from chronic, relapsing, or recurrent 
medical conditions: acute lymphoblastic leukaemia 
relapse (ﬁ ve), lymphoma (two), brain tumour (one), head 
trauma (one), vascular malformation (one), type 1 diabetes 
(one), relapse of nephrotic syndrome (two), infectious 
diseases (three), and heparin-induced thrombocytopenia 
type 2 (one); additionally, two adolescent girls were taking 
oral contraceptives. Rethrombosis occurred in three 
previously healthy individuals on no medication. 
Acute anticoagulation was undertaken with LMWH or 
unfractionated heparin in 250 children (65%), and 
165 patients of the entire cohort (43%) received continuous 
secondary anticoagulant prophylaxis: LMWH was given 
in 80% (126) of cases over a median period of 6 months 
(range 3–12), and 20% received warfarin over a period of 
12 months (6–84). Although all the other predictors 
(table 1) and rate of VT recurrence were similar in the 
participating countries (table 2), patients enrolled from 
the UK had a signiﬁ cantly lower rate of anticoagulant 
administration compared with children recruited from 
Israel and Germany (p=0·002). The distribution of 
infarction and haemorrhage on initial imaging, and the 
proportion of patients in whom anticoagulation was 
Israel Germany UK/Belgium Total
Surviving CVT population 50 (94%) 294 (98%) 40 (91%) 384 (98%)
Recurrences 2 of 50 (4%) 15 of 294 (5%) 5 of 40 (13%) 22 of 384 (6%)
In superﬁ cial sinuses
Sagittal* 2 (100%) 2 (13%) 1 (20%) 5 (23%)
Transverse* 0 3 (20%) 0 3 (14%)
In deep venous system
Deep veins 0 1 (7%) 0 1 (4.5%)
Straight sinus 0 2 (13%) 0 2 (9%)
At other locations
Cortical veins 0 2 (13%) 0 2 (9%)
VT/pelvic 0 2 (13%) 4 (80%) 6 (27%)
Pulmonary embolism 0 2 (13%) 0 2 (9%)
Intracardiac  0 1 (7%) 0 1 (4.5%)
Multiple thromboses: VT 
and sinuses*
0 2 (13%) 0 2 (9%)
Median follow-up, months 
(range) 
45 (6–85) 36 (6–72) 13 (0·1–48) 36 (0·1–85)
Deaths after CVT recurrence 1 (50%) 0 1 (20%) 2 (9%)
Prophylactic anticoagulation 
>6 months
39 of 50 (78%) 125 of 294 (43%) 1 of 40 (3%) 165 of 383 (43%)‡
LMWH 25 (64%) 101 (81%) 0 126 (76%)
Vitamin K-antagonists 14 (36%) 25 (20%) 1 (3%) 40 (24%)
Median (range) anticoagulation 
duration, months
6 (0–84) 3 (0–48) 24 6 (0–84)
3–6 months patency†/repeat 
MRV done
45 of 50 (90%) 200 of 294 (68%) 21 of 40 (53%) 266 of 383 (69%)‡
Complete 26 (58%) 89 (45%) 8 (38%) 123 (46%)
Persistent occlusion 2 (5%) 24 (12%) 4 (19%) 30 (11%)
Partial 17 (38%) 87 (44%) 9 (43%) 113 (42%)
Data are number (%) unless otherwise stated. *Combination of sagittal, superior and transverse sinus. †Conﬁ rmed by 
MRI/MRV in patients who had at least one MRV before recurrence. ‡n=383 (not 384) because of one early death after 
ﬁ rst CVT onset.
Table 2: Clinical characteristics of surviving population followed up for recurrence
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withheld due to bleeding symptoms at onset of CVT are 
shown in table 1. On unfractionated heparin, one adolescent 
girl developed heparin-induced thrombocytopenia type 2. 
One neonate on LMWH died with intracranial 
haemorrhage; one fatal intracerebral haemorrhage 
occurred in a child with intractable nephrotic syndrome 
anticoagulated with unfractionated heparin for recurrent 
CVT, and minor bleedings from puncture sites were 
documented in two further children treated with LMWH 
during the ﬁ rst CVT onset. No other child with 
antithrombotic therapy had a major haemorrhage 
subsequently. 
Only six of 22 patients (27%) were on secondary 
anticoagulation immediately before recurrent VT. 
Besides the adolescent girl who had heparin-induced 
thrombocytopenia type 2 on unfractionated heparin, 
three of the ﬁ ve children on prophylactic LMWH 
therapy showed reduced 4-h anti-factor Xa activity (0·1, 
0·25, and 0·34 IU/mL) at the time of recurrence. The 
other two children who relapsed on LMWH had 
adequate anti factor Xa activity. 
When comparing the treatment with the non-treatment 
group by univariate analysis, recurrence was commoner 
in children with underlying medical conditions than in 
those with idiopathic VT, but the diﬀ erence was not 
signiﬁ cant (p=0·124). In addition, when comparing the 
two treatment groups we noted no increase in the risk 
of recurrence for children in whom thrombophilia was 
diagnosed (p=0·852), or in children with the 
combination of a medical condition and prothrombotic 
disorder  (p=0·734). 
In ﬁ gure 2, the survival curves in children on 
anticoagulant administration compared with patients 
without anticoagulant before relapse are shown. 
Non-administration of anticoagulant in clinical 
situations that increase the risk of venous 
thrombosis—such as infections, dehydration, malignant 
disease, immobilisation, relapse of acute lymphoblastic 
leukaemia  or nephrotic syndrome, and in children with 
idiopathic CVT (n=3) was signiﬁ cantly associated with 
an increased risk of recurrence (log-rank test p<0·0001, 
ﬁ gure 2).
In addition to the 22 children with symptomatic 
recurrences, follow-up venography was undertaken in 
244 surviving children who remained free of clinical 
recurrence. Thus, 69% of cases had follow-up imaging, 
with 250 of 266 (94%) conﬁ rmed centrally by experienced 
neuroradiologists in the three study centres (Israel n=30; 
Germany n=203; Belgium and UK n=17). Patency was 
judged in children who had undergone MRV at CVT 
onset only. Our calculations showed substantial 
agreement (89·1%), beyond that expected by chance 
alone (41·1%), between local and central readers in the 
subset of 84 German patients tested (κ=0·82; 95% CI 
0·70–0·93; p<0·0001).
Compared with those with complete or partial patency 
of the initial sinuses involved, children with no patency at 
Number of 
patients with 
recurrences (%) 
Cumulative 
number of 
patients with 
recurrences (%)
Cumulative number 
of patients without 
recurrent VT or 
death  (%)
<1 4 (1·0%) 4 (18%) 380 (99%)
1 to <3 6 (1·5%) 10 (45%) 374 (97%)
3 to <6 5 (1·3%) 15 (68%) 369 (96%)
6 to <12 2 (0·5%) 17 (77%) 367 (96%)
12 to <24 3 (0·8%) 20 (91%) 364 (95%)
24 to <36 1 (0·3%) 21 (95%) 363 (95%)
>36 1 (0·3%) 22 (100%) 362 ( 94%)
Table 3: Timing (months after ﬁ rst CVT onset) of VT recurrences in 
384 surviving patients with CVT
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Figure 1: Cumulative thrombosis-free survival with respect to age at ﬁ rst thrombosis onset 
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Figure 2: Cumulative thrombosis-free survival in children with and without anticoagulation before recurrent VT
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follow-up venous imaging had a shorter thrombosis-free 
survival for CVT and non-CVT recurrence (table 4). The 
combined data for CVT and VT recurrences are shown in 
ﬁ gure 3.
Multivariate analysis was done in three steps. The ﬁ rst 
included the signiﬁ cant predictors derived from univariate 
Kaplan-Meier analysis—ie, age at ﬁ rst CVT onset, 
non-administration of anticoagulant before relapse, and 
persistent venous occlusion (table 4). The second analysis 
included three potential prothrombotic risk factors. Cox 
regression analysis showed that the heterozygous factor II 
G20210A mutation was a signiﬁ cant risk factor for 
recurrent VT in the present cohort (table 4). The 
heterozygous factor V G1691A mutation and raised 
lipoprotein (a) were not associated with an increased risk 
of recurrent VT. Additionally, no recurrent VT was 
diagnosed in two children with antithrombin deﬁ ciency, 
in two with protein C deﬁ ciency, or in ﬁ ve in whom 
persistent anticardiolipin antibodies or lupus 
anticoagulants were reported. According to the current 
standard of care, children with persistent anticardiolipin 
antibodies or lupus anticoagulants were on long-term 
anticoagulation with warfarin.30 The third proportional 
hazards analysis, which included signiﬁ cant predictors 
from the ﬁ rst two steps, showed that non-administration 
of anticoagulation before relapse, persistent venous 
occlusion, and being heterozygous for G20210A mutation 
in factor II were independent risk factors for recurrent VT 
in the cohort (table 4). Possible interaction eﬀ ects between 
predictors were assessed with the Wald test: p values were 
0·636 for persistent venous occlusion and factor II 
G20210A mutation, 0·707 for previous anticoagulation 
and factor II G20210A mutation, and 0·982 for persistent 
venous occlusion and previous anticoagulation. The 
likelihood ratio test, used to further test the overall 
hypothesis of no eﬀ ect of all predictors in the ﬁ nal model, 
gave a p value of <0·0001. Since no comparable paediatric 
CVT cohort was currently available to validate the 
hypothesis derived from the ﬁ nal statistical model, we did 
an internal validation. Results of the Hosmer-Lemeshow 
goodness-of-ﬁ t test (p=0·586) gave evidence that the ﬁ nal 
model predicts outcome in the cohort investigated. 
The number needed to screen to detect at least one 
factor II G20210A carrier was 16, the overall number 
needed to treat to prevent one recurrent VT was 32 for the 
whole group and three in carriers of the factor II mutation 
who were older than 2 years at ﬁ rst thrombotic onset. 
Discussion
In this group of paediatric CVT patients from three 
European registries, the overall yearly rate of a second 
VT event was 22·2 per 1000 person-years within a 
median period of 6 months after ﬁ rst VT onset. Our 
data are in accord with ﬁ ndings on cerebral vein and 
dural sinus thrombosis in adult patients;39–43 the 
cumulative recurrence rate of either CVT or any other 
thrombotic event in these studies ranged from 0% 
to 26%. Ferro and colleagues reported in their series of 
624 adults that 58·8% of patients were not under any 
anticoagulant treatment at time of recurrence.41 In these 
studies, recurrent events occurred over a mean follow-up 
period of 18–77 months in patients without anticoagulant 
at the time of recurrence who had previously completed 
a standard 3–6 months course of anticoagulant 
treatment,39–43 but the eﬀ ect of patency rates on 
recurrence was not addressed.
Figure 3: Cumulative thrombosis-free survival in children with complete, partial, and no patency at 3–6 months 
Analysis included only patients for whom full patency data were available (n=266); in the other patients, early second 
events occurred before completion of patency follow-up. Recurrences in children with full data: four complete, three 
partial, eight none.
HR (95% CI) p
First step (ref: anticoagualation before relapse, any recanalisation)
Age at onset (months) 1·0 (0·99–1·01) 0·090
No anticoagulation before relapse 16·1 (4·3–60·9) <0·0001
Persistent CVT occlusion
CVT and VT recurrence 5·1 (1·6–16·1) 0·005
CVT recurrence alone 5·4 (1·3–22·8) 0·019
VT recurrence alone 9·1 (1·7–49·5) 0·010
Second step (ref: factor II wild type, FV wild type, lipoprotein (a) 
<300 mg/L
Factor II G20210A 5·5 (1·5–20·8) 0·011
Factor V G1691A 1·9 (0·2–14·9) 0·530
Lipoprotein (a) >300 mg/L 0·9 (0·3–3·0) 0·868
Third step (ref: anticoagulation before relapse, any recanalisation, 
factor II wild type)
No anticoagulation before relapse 11·2 (3·4–37·0) <0·0007
Persistent CVT occlusion 4·1 (1·1–14·8) 0·032
Factor II G20210A 4·3 (1·1–16·2) 0·034
Table 4: Three-step Cox proportional hazards model 
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Our survival analysis suggests that in children older 
than 2 years, failure to recanalise and the presence of the 
G20210A mutation in factor II are risk factors for 
recurrent VT. Interestingly, failure to recanalise predicted 
CVT and non-CVT recurrence when both were assessed 
independently. A possible mechanism aﬀ ecting 
thrombus formation and clot patency rates is the stability 
of the clot itself, which might depend not on the 
anatomical venous location but on other factors, 
including genetic polymorphisms, for example in the 
ﬁ brinogen or the factor XIII gene. Iron deﬁ ciency might 
also play a part in failure to recanalise,2 which might be a 
reason why this factor aﬀ ects risk of recurrence 
independently of anticoagulant treatment; we could not 
conﬁ rm such an association, because we did not have 
these data for most patients. Our observations about 
common thrombophilias were in line with those of a 
meta-analysis in adults, which showed an estimated 
population-attributable risk for recurrence of 6·7 (95% CI 
3·4–9·9) for the factor II G20210A variant, but could not 
conﬁ rm this risk for the heterozygous factor V G1691A 
mutation, with an estimated population attributable 
recurrence risk of 9·0 (95% CI 4·5–13·2) in adult 
patients with VT.44 
Our data also show an increased risk for recurrent VT 
in children with a ﬁ rst CVT onset after age 2 years, with a 
recurrence rate per 1000 person-years in accord with data 
reported in adult European patients with CVT.39–42 
Additionally, our results provide evidence that the use of 
anticoagulants should be considered on an individual 
patient basis in clinical situations where the risk of 
venous thrombosis is increased. The prolonged use of 
such drugs in a physically active age group must be 
weighed against the risk of haemorrhage. Since the 
number needed to treat to prevent one recurrent VT in 
this cohort was 32, prolonged anticoagulation might only 
be justiﬁ ed in children older than 2 years who also carry 
the factor II mutation (number needed to treat=three), in 
those with idiopathic CVT—ie, with no pre-existing 
illness or triggers, or in children in whom recurrent VT 
has already occurred. Practically, rather than receiving 
indeﬁ nite anticoagulation, children with chronic 
conditions associated with VT might require such 
treatment only in high-risk situations—eg, postoperatively, 
if prolonged immobilisation is needed, or if the patient 
becomes dehydrated. 
The rate of recurrent thrombosis over a median 
follow-up period of 36 months reported here is lower than 
that previously reported in children,1,2 probably because 
prolonged anticoagulation was undertaken in 65% of the 
German and Israeli patients over a period of at least 
6 months, whereas in the UK-Belgian and Canadian 
studies only 40% and 53% of patients, respectively, 
received antithrombotic therapy over the ﬁ rst 3 months.1,2 
We report a low rate of recurrence in children aged 
2 years and younger, and a median age of 13 years at 
second VT in children older than 2 years at onset. Since 
the younger children all passed the ﬁ rst risk period of 
childhood thrombosis—ie, the ﬁ rst year of life—we 
propose that peculiarities of developmental haemostasis 
associated with the well-known second peak of VT risk 
during puberty and adolescence, via hormonal changes 
and a downregulation of the ﬁ brinolytic system, 
contribute to the increasing recurrence rate reported 
here.45 This proposal is supported by Goldenberg and 
colleagues’35 ﬁ nding that children with deep venous 
thrombosis are more likely to have a recurrence during 
puberty. 
The potential biases due to including only data from 
centres with an interest in paediatric CVT, 
non-randomisation of treatment methods, and use of 
diﬀ erent imaging methods to diagnose CVT at ﬁ rst onset, 
are limitations of our follow-up study. A larger 
international treatment study is needed to answer the 
open questions. The mode of anticoagulation which in 
accord with published paediatric guidelines was 
recommended by the treating physicians, was the major 
source of heterogeneity of the pooled patient cohorts. 
Anticoagulation regimens recommended for children 
and known to act on an equivalent basis in adult patients 
with VT were used.29,30 Patients recruited from the UK 
had a signiﬁ cantly lower rate of anticoagulant 
administration than children recruited from Israel and 
Germany, but the prevalences of the other factors used to 
predict recurrence were similar. Based on the work of 
Revel-Vilk and coworkers,34 who showed in an 
independent cohort that VT patency at follow-up in 
children with venous thromboses was not related to 
anticoagulation therapy, and supported by our ﬁ nding of 
no signiﬁ cant diﬀ erences between the recurrence rates 
in the three study countries, we believe that pooling of 
the three registries was a valid way to address the 
important question of recurrence risk in relation to 
anticoagulation. However, further work is needed. 
Central reading of acute and follow-up imaging for all 
patients with assessment of interobserver variability 
would be an important component of a prospective study, 
which would ideally be population-based. The data 
obtained from our ﬁ nal model should also be validated in 
a diﬀ erent cohort of patients with a ﬁ rst onset of CVT; 
the opportunity to undertake such a study in partnership 
with the International Paediatric Stroke Study 
collaboration is currently under investigation. The 
strength of this study is that in the large European cohort, 
the rate of recurrent VT after CVT in children was 
comparable between diﬀ erent countries, which allows us 
to better calculate the number of patients that need to be 
enrolled to suﬃ  ciently power a randomised treatment 
study. Until data from such studies are available, the 
message of this follow-up study is clearly that 
administration of secondary anticoagulation prophylaxis 
should be considered on an individual patient basis in 
children with newly identiﬁ ed CVT in situations where 
the risk of VT is high.
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